Offer Description

- Responsible for clinical / patient data acquisition and management;
- Managing data for complex studies within agreed timescales;
- Responsible for implementing systems to monitor timeliness of data entry;
- Manage a team of data staff to ensure data is entered and site files are managed providing a high-quality data service to Principal Investigators and study teams. Responsible for clinical / patient data acquisition and management;
- Managing data for complex studies within agreed timescales;

Cancer is one of the leading causes of death worldwide, and it brings with it significant emotional, social, economic, and public health challenges.
Prevention is a crucial tool in the fight against cancer. By identifying risks early, it not only saves lives and reduces suffering but also helps conserve valuable healthcare resources, both human and financial.

The patient has multiple myeloma, one of the most common haematological (blood) cancers worldwide.

In patients under the age of 70, the first-line treatment for this cancer includes harvesting the patient's own cells, known as “haematopoietic progenitor cells”, intensive chemotherapy and, finally, reinfusion of the previously harvested cells. These haematopoietic progenitor cells are capable of giving rise to all types of blood cells normally produced by the bone marrow.

Additionally, we will explore the ongoing evolution of minimally invasive techniques and their impact on the patient's quality of life, even on complex cases, such as lateral compartment resections in rectal cancer and D3 lymphadenectomy in colon cancer.

“Surgery can cure”, said Markus Büchler, director of the newly opened Botton-Champalimaud Pancreatic Cancer Centre, in Lisbon, during his talk. Büchler was referring to a form of pancreatic cancer surgery called the “triangle operation”, which he invented and developed.

Host

Klaas van Gisbergen, PhD, Tissue Immunity Lab

Venue

Seminar room

For this edition of the contest, a total of nine groundbreaking biomedical and health projects spearheaded by research institutions in Portugal were selected. Alongside CF, GIMM, and i3S, awards were also granted to projects from the Instituto de Tecnologia Química e Biológica António Xavier da Universidade Nova de Lisboa (ITQB NOVA), Instituto de Investigação em Ciências da Vida e da Saúde (ICVS) and Instituto de Biomedicina (iBiMED). These nine selected projects will receive more than €7.6 million in support.